ATE266409T1 - Synergistische wirkung von glyburide und milrinone - Google Patents

Synergistische wirkung von glyburide und milrinone

Info

Publication number
ATE266409T1
ATE266409T1 AT01303020T AT01303020T ATE266409T1 AT E266409 T1 ATE266409 T1 AT E266409T1 AT 01303020 T AT01303020 T AT 01303020T AT 01303020 T AT01303020 T AT 01303020T AT E266409 T1 ATE266409 T1 AT E266409T1
Authority
AT
Austria
Prior art keywords
sulfonylurea
diabetic
channel blocker
atp channel
inhibitor
Prior art date
Application number
AT01303020T
Other languages
English (en)
Inventor
David Albert Fryburg
Janice Catherine Parker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE266409T1 publication Critical patent/ATE266409T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Paper (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01303020T 2000-04-13 2001-03-30 Synergistische wirkung von glyburide und milrinone ATE266409T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19672800P 2000-04-13 2000-04-13

Publications (1)

Publication Number Publication Date
ATE266409T1 true ATE266409T1 (de) 2004-05-15

Family

ID=22726606

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01303020T ATE266409T1 (de) 2000-04-13 2001-03-30 Synergistische wirkung von glyburide und milrinone

Country Status (12)

Country Link
US (2) US6610746B2 (de)
EP (1) EP1145717B1 (de)
JP (1) JP2001354568A (de)
AT (1) ATE266409T1 (de)
BR (1) BR0101461A (de)
CA (1) CA2343850A1 (de)
DE (1) DE60103203T2 (de)
DK (1) DK1145717T3 (de)
ES (1) ES2218338T3 (de)
MX (1) MXPA01003853A (de)
PT (1) PT1145717E (de)
TR (1) TR200401145T4 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2809310B1 (fr) * 2000-05-26 2004-02-13 Centre Nat Rech Scient Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
CA2369967A1 (en) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
SE0101980D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
SE0101981D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
EP1430140B1 (de) 2001-08-01 2010-09-15 University of Utah Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
EP2438913B1 (de) * 2002-03-20 2020-05-06 University of Maryland, Baltimore Nicht-selektiver Kationenkanal in neuralen Zellen und Verfahren zur Behandlung von Hirnschwellung
WO2003097064A1 (en) * 2002-05-17 2003-11-27 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for diabetes
CN1964630A (zh) * 2003-02-13 2007-05-16 耶希瓦大学艾伯塔·爱恩斯坦医学院 通过控制下丘脑的长链脂肪酰基－辅酶A(LC－CoA)的水平来调控食物摄取和葡萄糖产生
EP1722120A4 (de) * 2004-03-02 2012-10-24 Ntn Toyo Bearing Co Ltd Rotationsübertragungsvorrichtung
PL381247A1 (pl) * 2004-03-04 2007-05-14 Kissei Pharmaceutical Co., Ltd. Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja lecznicza, oraz jej zastosowanie lecznicze
ES2543836T3 (es) * 2004-04-23 2015-08-24 Northern Sydney Local Health District Procedimientos y composiciones para el tratamiento de afecciones miocárdicas
JP5085326B2 (ja) * 2004-09-18 2012-11-28 ユニバーシティ オブ メリーランド，ボルチモア ＮＣＣａ−ＡＴＰチャネルを標的とする処置剤およびその使用方法
EP1802313B1 (de) * 2004-09-18 2010-11-03 University of Maryland, Baltimore Therapeutische mittel zum targeting des ncca-atp-kanals und verwendungsverfahren dafür
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
US20090012067A1 (en) * 2005-02-14 2009-01-08 Luciano Rossetti Modulation of Hypothalamic Atp-Sensitive Potassium Channels
US20110165236A1 (en) * 2006-09-22 2011-07-07 Biokey, Inc. Controlled release hydrogel formulation
US20080075785A1 (en) * 2006-09-22 2008-03-27 San-Laung Chow Controlled release hydrogel formulation
US9511075B2 (en) * 2007-01-12 2016-12-06 The University Of Maryland, Baltimore Targeting NCCA-ATP channel for organ protection following ischemic episode
EP2114160B1 (de) * 2007-02-09 2016-11-16 University of Maryland, Baltimore Antagonisten eines nicht selektiven kationenkanals in nervenzellen
CA2691199C (en) 2007-06-22 2017-09-12 Marc J. Simard Inhibitors of ncca-atp channels for therapy
JP2010168301A (ja) * 2009-01-22 2010-08-05 Kitasato Institute 中枢循環改善薬
CN103372013A (zh) * 2013-06-28 2013-10-30 上海交通大学医学院附属瑞金医院 米力农在制备治疗糖尿病足溃疡药物方面的应用
US10624923B2 (en) 2014-03-26 2020-04-21 Enrique G. Gutierrez Compositions and related methods for treating and preventing viral and retroviral infections
US11260074B2 (en) 2014-03-26 2022-03-01 Enrique G. Gutierrez Compositions and related methods for reconstituting the immune system of a subject

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

Also Published As

Publication number Publication date
US20020013268A1 (en) 2002-01-31
TR200401145T4 (tr) 2004-07-21
US20030216294A1 (en) 2003-11-20
CA2343850A1 (en) 2001-10-13
PT1145717E (pt) 2004-08-31
DE60103203T2 (de) 2005-05-04
EP1145717A3 (de) 2002-08-14
BR0101461A (pt) 2001-11-13
EP1145717A2 (de) 2001-10-17
DE60103203D1 (de) 2004-06-17
US6610746B2 (en) 2003-08-26
ES2218338T3 (es) 2004-11-16
JP2001354568A (ja) 2001-12-25
DK1145717T3 (da) 2004-08-02
EP1145717B1 (de) 2004-05-12
MXPA01003853A (es) 2005-06-30

Similar Documents

Publication Publication Date Title
ATE266409T1 (de) Synergistische wirkung von glyburide und milrinone
CA2474578A1 (en) Novel pyridin- and pyrimidin-derivatives
DE69213892D1 (de) Aromatische Aminoalkoholderivate mit antidiabetischer und Antiobesitäts-Wirkung, ihre Herstellung und therapeutische Verwendung
MXPA05011702A (es) Agentes antidiabeticos.
IL118474A0 (en) Benzimidazole derivatives pharmaceutical compositions containing the same and the use thereof
DK1088824T3 (da) Bicykliske pyrrolylamider som glycogen phosphorylase inhibitorer
BR0107901A (pt) Composto, composição farmacêutica, método para o trtamento de enfermidade, para o trtamento e/ou prevenção de condições mediadas por receptores nucleares, e para o tratamento e/ou prevenção de diabetes e/ou obesidade, uso de um composto, e, método para tratar diabetes de tipo i, diabetes de tipo ii, tolerância à gligose prejudicada, resistência à insulina ou obesidade
BR0213539A (pt) Compostos, processo para a preparação de compostos, composições farmacêuticas que compreendem um composto método para o tratamento e/ou profilaxia de enfermidades que estão associadas com dpp iv e utilização desses compostos
AR032065A1 (es) Derivados de glucopiranosiloxipirazol y composicion farmaceutica
BR0209468A (pt) Composto ou sais ou solvatos deste farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada pelo hppar
MX2007004003A (es) Composiciones de amitraz.
BR0211414A (pt) Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e de diabetes tipo i, diabetes tipo ii, tolerância à glicose, resistência à insulina ou obesidade prejudicadas
BR0314335A (pt) Composto, uso do mesmo, composição farmacêutica, e métodos para o tratamento e/ou prevenção de condições mediadas por receptores nucleares, e de diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glicose, resistência à insulina ou obesidade
GEP20084490B (en) Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses thereof
BR0215032A (pt) Composição herbicidamente ativa, método para controlar vegetação indesejável, e, uso de composições
NO20040153L (no) Synergistisk farmasoytisk kombinasjon for profylakse eller behandling av diabetes
BR0107902A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças, e para o tratamento e/ou prevençao de, condições mediadas por receptores nucleares, e diabetes e/ou obesidade, uso de uim composto, processo para a preparação de um composto, e, método para tratar diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glucose, resistência à insolina ou obesidade
BR0209650A (pt) Análogos de adenosina para o tratamento da sìndrome de resistência à insulina e da diabetes
ATE518544T1 (de) Rotbusch-extrakt gegen diabetes
BR0314419A (pt) Compostos de 5-croman-5-il-etilamina substituìdos, seu uso e composição farmacêutica incluindo-o
EP1413308A4 (de) Hypoglykämisches mittel
BR9913149A (pt) Derivados de piperazina antidiabéticos, processos para sua preparação e composições contendo os mesmos
ATE380799T1 (de) Biguanid-derivate und deren verwendung als antidiabetika
DK0444546T3 (da) Hydantoinderivater til anvendelse som hypoglycæmiske og/eller hypolipidæmiske midler
CO5690542A2 (es) Metodo para la produccion de derivados de acil-fenil-urea sustituidos por animo-carbonilo y el uso de los mismos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1145717

Country of ref document: EP

REN Ceased due to non-payment of the annual fee